SCIDOT-52. IN SITU DELIVERY OF TUMOR TREATING FIELDS THERAPY IN GLIOBLASTOMA PATIENTS

The efficacy of Tumor-Treating Fields (TTFields) rests on the result of a large-scale clinical trial that demonstrated an increase in the survival of newly diagnosed glioblastoma patients when combined with temozolomide chemotherapy. Overall survival now extends to over 60 months in some of our pati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Arle, Jeffrey, Wong, Eric, Korshoej, Anders, Dokos, Socrates, Bomzon, Ze’ev, Carlson, Kristen
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Abstracts from the 3rd Sno-Scidot Joint Conference on Therapeutic Delivery to the CNS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846844/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.1187
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars